Indevus/Pliva Co-Promotion Deal Puts 481 Reps Behind Incontinence Drug Sanctura

Sanctura (trospium) is currently pending at FDA with a May 28 user fee goal date. Indevus' overactive bladder treatment will face competition from upcoming agents by marketing heavyweights Novartis (Enablex) and GlaxoSmithKline/Yamanouchi (Vesicare); both are "approvable" at FDA.